Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Sabizabulin - Veru Healthcare

Drug Profile

Sabizabulin - Veru Healthcare

Alternative Names: APP-111; Bisindole; VERU-111

Latest Information Update: 07 Feb 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Ohio State University; University of Tennessee Research Foundation
  • Developer University of Tennessee Research Foundation; Veru Healthcare
  • Class Anti-inflammatories; Antineoplastics; Antivirals; Imidazoles; Indoles; Ketones; Phenyl ethers; Small molecules
  • Mechanism of Action Tubulin inhibitors; Tubulin polymerisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preregistration COVID 2019 infections
  • Phase III Ebola virus infections; Prostate cancer; Smallpox
  • Phase II SARS-CoV-2 acute respiratory disease
  • Preclinical HER2 positive breast cancer
  • Suspended Influenza A virus H1N1 subtype
  • No development reported Solid tumours

Most Recent Events

  • 07 Feb 2024 Suspended - Phase-II for Influenza A virus H1N1 subtype (PO) due to lack of funding
  • 25 Jan 2024 Sabizabulin - Veru Healthcare is available for licensing as of 25 Jan 2024. https://verupharma.com/pipeline/
  • 26 Sep 2023 FDA approves phase III clinical trial study to evaluate sabizabulin 9mg for the broader treatment of hospitalized adult patients who have any type of viral ARDS
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top